Market Overview:
The global atazanavir market is expected to grow from USD 1.5 billion in 2018 to USD 2.8 billion by 2030, at a CAGR of 9.7% during the forecast period. The growth of the global atazanavir market is attributed to the increasing prevalence of HIV/AIDS, rising demand for novel antiretroviral therapies, and growing number of clinical studies evaluating the safety and efficacy of atazanavir-based regimens. However, patent expiries for key players are expected to restrain the growth of this market during the forecast period. Based on type, the global atazanavir market is segmented into 150 mg capsule, 200 mg capsule, 300 mg capsule, and 50 mg oral powder. The 150 mg capsule segment is projected to account for a larger share in terms of revenue than other segments during the forecast period owing to its high adoption rate across regions due to its lower dosage requirement as compared with other dosages available in this market space. By application,, adults accounted for a larger share og revenue than children 3 months old or older in 2017; however,.
Product Definition:
Atazanavir is a protease inhibitor used to treat HIV infection. It is often used in combination with other antiretroviral medications. Atazanavir is important because it helps to decrease the amount of virus in the body, which can improve survival rates and reduce the risk of illness.
150 mg Capsule:
150 mg capsule is used for the treatment of HIV-1 infection and aids in boosting the immune system. It also helps to reduce the amount of virus by decreasing its activity. Increasing demand for 150 mg capsules due to their efficiency in treating HIV-1 infection is expected to drive market growth over the forecast period.
200 mg Capsule:
200 mg capsule is used for the treatment of HIV-1 infection and aids in boosting the immune system. It works by decreasing levels of viral proteins that bind to CD4 cells, leading to fewer viral particles being produced.
U.S 200 mg Capsule Market Size, Share & Trends Analysis Report By Application (HIV-1 Infection Treatment), By Route Of Administration (Oral), And Segment Forecasts, 2018 - 2025 -> The U.
Application Insights:
The adults segment held the largest share of over 70.0% in 2017. The growing use of atazanavir to treat HIV/AIDS and other diseases is expected to be a major factor for this growth. In addition, the presence of strong distribution channels that offer atazanavir in oral form coupled with high awareness regarding this medication among patients is anticipated to drive growth during the forecast period.
The children segment was valued over USD 40 million in 2017 owing to high prevalence rate of Ataxia-telangiectasia (A-T) disease and other rare disorders caused by mutations in ATM gene, which results in unavailability or deficiency of ATM protein leading to loss of motor neurons and paralysis respectively.
Regional Analysis:
North America dominated the global market in terms of revenue with a share of over 40.0% in 2017. This is attributed to the high prevalence of HIV and subsequently increasing demand for anti-retroviral drugs, supportive healthcare infrastructure, and high disposable income among people living with HIV/AIDS. Moreover, government initiatives promoting awareness about treatment options are expected to fuel product demand during the forecast period.
Asia Pacific atazanavir market is expected to witness lucrative growth over the forecast period owing to rising disposable income especially in developing countries such as India and China along with growing target population base due to increased incidence rate of COVID-19 Highly Pathogenic Avian Influenza (HPAI). These factors are anticipated boost product sales across this region during the estimated time span.
Growth Factors:
- Increasing incidence of HIV/AIDS: The global incidence of HIV is on the rise, with an estimated 36.7 million people living with the virus in 2016. This is expected to drive demand for atazanavir and other antiretroviral drugs in the coming years.
- Growing awareness about HIV/AIDS: There has been a growing awareness about HIV and its treatment in recent years, which is likely to boost demand for atazanavir and other antiretroviral drugs in the coming years.
- Rising prevalence of multi-drug resistant strains of HIV: The prevalence of multi-drug resistant strains of HIV is on the rise, posing a major challenge to healthcare providers worldwide. This is likely to drive demand for atazanavir and other second-line antiretroviral drugs in the coming years.
- increasing affordability of atazanavir: Atazanvir has become increasingly affordable over the past few years, making it more accessible to patients across the globe. This is likely to boost demand for atazanvir in the coming years.. 5) Expanding patient population base: The patient population base for diseases such as AIDS continues to expand globally, providing a large potential market for atraznavir and other antiretroviral drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Atazanavir Market Research Report
By Type
150 mg Capsule, 200 mg Capsule, 300 mg Capsule, 50 mg Oral Powder
By Application
Adults, Children 3 months of age and older
By Companies
Bristol-Myers Squibb, TEVA, Cipla, Mylan, Aurobindo Pharma, Emcure, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Atazanavir Market Report Segments:
The global Atazanavir market is segmented on the basis of:
Types
150 mg Capsule, 200 mg Capsule, 300 mg Capsule, 50 mg Oral Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children 3 months of age and older
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- TEVA
- Cipla
- Mylan
- Aurobindo Pharma
- Emcure
- Bristol-Myers Squibb
Highlights of The Atazanavir Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 150 mg Capsule
- 200 mg Capsule
- 300 mg Capsule
- 50 mg Oral Powder
- By Application:
- Adults
- Children 3 months of age and older
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atazanavir Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atazanavir is a medication used to treat HIV infection. It works by blocking the virus from entering cells and replicating.
Some of the key players operating in the atazanavir market are Bristol-Myers Squibb, TEVA, Cipla, Mylan, Aurobindo Pharma, Emcure, Bristol-Myers Squibb.
The atazanavir market is expected to register a CAGR of 9.7%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Atazanavir Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Atazanavir Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Atazanavir Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Atazanavir Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Atazanavir Market Size & Forecast, 2020-2028
4.5.1 Atazanavir Market Size and Y-o-Y Growth
4.5.2 Atazanavir Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 150 mg Capsule
5.2.2 200 mg Capsule
5.2.3 300 mg Capsule
5.2.4 50 mg Oral Powder
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Adults
6.2.2 Children 3 months of age and older
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Atazanavir Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Atazanavir Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 150 mg Capsule
9.6.2 200 mg Capsule
9.6.3 300 mg Capsule
9.6.4 50 mg Oral Powder
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Adults
9.10.2 Children 3 months of age and older
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 150 mg Capsule
10.6.2 200 mg Capsule
10.6.3 300 mg Capsule
10.6.4 50 mg Oral Powder
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Adults
10.10.2 Children 3 months of age and older
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 150 mg Capsule
11.6.2 200 mg Capsule
11.6.3 300 mg Capsule
11.6.4 50 mg Oral Powder
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Adults
11.10.2 Children 3 months of age and older
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 150 mg Capsule
12.6.2 200 mg Capsule
12.6.3 300 mg Capsule
12.6.4 50 mg Oral Powder
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Adults
12.10.2 Children 3 months of age and older
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 150 mg Capsule
13.6.2 200 mg Capsule
13.6.3 300 mg Capsule
13.6.4 50 mg Oral Powder
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Adults
13.10.2 Children 3 months of age and older
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Atazanavir Market: Competitive Dashboard
14.2 Global Atazanavir Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 TEVA
14.3.3 Cipla
14.3.4 Mylan
14.3.5 Aurobindo Pharma
14.3.6 Emcure
14.3.7 Bristol-Myers Squibb
